Coherent files premarket approval application (PMA) for lung cancer therapy:
This article was originally published in Clinica
Executive Summary
Coherent has filed a supplemental PMA with the FDA for its photodynamic therapy (PDT) for the treatment of lung cancer. PDT uses laser light to stimulate a light-sensitive, cancer-specific drug to destroy host tumour cells. The light is administered to tissue that contains the drug via a fibre optic delivery system. Coherent, based in Santa Clara, California, received FDA approval last year of its PDT system for the treatment of some advanced forms of oesophageal cancer.